Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
By N. Hunder, H. Wallen, Jianhong Cao, Deborah W. Hendricks, J. Z. Reilly, Rebecca M. Rodmyre, A. Jungbluth, S. Gnjatic, John A Thompson, C. Yee. New England Journal of Medicine, 2008
943 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/a1e3d4d6251f8d87906720939599424e74c978b6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response (2014, background): “The adoptive transfer of an in vitro sensitized autologous CD4þ T-cell clone that recognized an HLA-DP 04 restricted NY-ESO-1 peptide mediated regression of metastatic melanoma in 1 of 9 patients (16, 18).”
- Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011, background): “The adoptive transfer of an in vitro sensitized autologous CD4 T-cell clone that recognized the HLA-DP*04–restricted NY-ESO-1:157-170 peptide epitope mediated regression of metastatic melanoma in one of nine patients.(16,25) The results presented in this report indicate that the frequency of T cells”
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma (2008, background): “Needle biopsy specimens of necrotic tumor sites from subjects 6, 8 and 10, although revealing T cell infiltrates, lacked PCR signal for CAR-CTLs or CAR-ATCs, suggesting that the observed tumor responses may have resulted from indirect mechanisms of cytotoxicit”
- Cancer immunotherapy (2012, background): “The composition of intestinal flora has been shown in preclinical models to have a profound impact on the manifestation of autoimmune diseases, such as inflammatory bowel disease and rheumatoid arthritis (Ivanov et al., 2009; Wu et al., 2010; Ivanov and Littman, 2011).”
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts (2010, background): “Although initially focused on CD8+ CTL responses (Yee et al., 2002), recent preclinical and clinical studies have redirected attention to CD4+ T cells, which are thought to provide the necessary help to the effector CD8+ CTL compartment (Hunder et al., 2008).”
- Adoptive immunotherapy for cancer: harnessing the T cell response (2012, neutral): “Güz Sayısı 2012 | Cilt:5 | Sayı:6 İmmünoloji Çalışma Grubu 2012 (145) bir hastanın tam bir cevap gösterdiği vurgulanmıştır (146).”